What is the relationship between anti‑thyroglobulin antibodies (anti‑Tg) and thyroglobulin (Tg)?

Relationship Between Anti-Thyroglobulin Antibodies and Thyroglobulin

Anti-thyroglobulin antibodies (anti-Tg/TgAb) interfere with thyroglobulin (Tg) measurement by binding to Tg protein, causing falsely low or undetectable Tg results in immunoassays, which occurs in up to 30% of differentiated thyroid cancer patients. 1

The Core Relationship

Thyroglobulin is a dimeric glycoprotein produced exclusively by normal thyroid follicular cells and differentiated thyroid cancer (DTC) cells 1. Anti-Tg antibodies are autoantibodies directed against this Tg protein. When present, these antibodies create a critical clinical problem: they bind to Tg molecules in the patient's serum, interfering with immunometric assays that attempt to measure Tg levels 1.

Mechanism of Interference

The interference occurs through several mechanisms:

• Direct binding: TgAb binds to Tg epitopes, preventing assay antibodies from accessing the protein 2
• Dose-dependent effect: Higher TgAb concentrations generally cause greater underestimation of Tg, though this relationship is not universal across all patients 3
• Epitope specificity: The number of different Tg epitopes recognized by TgAb correlates inversely with Tg recovery (r = -0.66; P <0.001), meaning broader antibody recognition causes more interference 2
• Variable impact: TgAb can cause 15-50% underestimation of true Tg values 3

Clinical Implications

Why This Matters

TgAb must always be measured alongside Tg in DTC monitoring because false-negative Tg results can mask disease recurrence. 1, 4 This is particularly critical since:

• Up to 30% of DTC patients have TgAb present 1
• Even when Tg recovery tests appear normal (median 94% even with elevated TgAb), interference can still occur on an individual basis 5
• Tg recovery testing lacks sufficient precision and specificity to reliably detect interference in single specimens 5

Using TgAb as a Surrogate Marker

When TgAb interferes with Tg measurement, the trend in TgAb levels itself becomes a valuable prognostic marker 6:

• Declining TgAb concentrations suggest disease remission
• Rising TgAb titers may indicate recurrence
• A postoperative TgAb threshold of 440 IU/mL predicts higher recurrence risk (13.3% vs lower levels) with an odds ratio of 6.0 (95% CI: 2.987-12.053) 7

Important Caveats

1. Not all TgAb causes clinically significant interference: Low-level TgAb is often clinically irrelevant; higher titers (particularly >440 IU/mL) are more problematic 6, 7

2. A negative TgAb does not completely exclude interference: While it reduces likelihood, it doesn't guarantee accurate Tg measurement 4

3. Individual variability exists: The dose-dependent relationship between TgAb and Tg underestimation occurs in some but not all patients 3

4. Assay-specific performance varies: Different Tg immunoassays have varying susceptibility to TgAb interference 1, 6

Practical Algorithm

When monitoring DTC patients:

1. Always measure both Tg and TgAb simultaneously 1, 4
2. If TgAb is positive (especially >440 IU/mL):
   • Consider Tg result potentially unreliable
   • Monitor TgAb trends as surrogate marker 6, 7
   • Rising TgAb = possible recurrence
   • Falling TgAb = likely remission
3. If TgAb is negative: Tg measurement is more reliable (though not guaranteed interference-free) 4
4. Serial measurements are more valuable than single values for both Tg and TgAb 1